Pulsatile FXR activation for liver diseases.
Where this comes from
- Record sourced from PubMed, PMID 42551414.
- Also identified by DOI 10.1016/j.cmet.2026.07.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sustained receptor activation is often prioritized in drug development. Zang and colleagues challenge this paradigm with linafexor, a rapidly cleared farnesoid X receptor agonist that produces pulsatile activation, preserves receptor responsiveness, reduces broad transcriptional disruption, and improves efficacy and safety, highlighting temporal alignment as a design principle for metabolic therapeutics.
Medical subject headings
- Receptors, Cytoplasmic and Nuclear
- Liver Diseases